RARS1

Across TCGA pan-cancer cohorts, RARS1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RARS1 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RARS1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RARS1 expression acts as an unfavorable survival marker.

LUAD, CCRCC, and GBM are the cancer types where RARS1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.487	0.848	.001	27	view →
CCRCC	OS	Quartile	All	0.701	0.962	.001	23	view →
GBM	DFS	Tertile	All	0.650	0.836	.012	8	view →
LSCC	OS	Median	III,IV	0.522	0.859	.026	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RARS1–LUAD (DFS)

Open the LUAD breakdown →